Imatinib is a small molecule kinase inhibitor. Gleevec film-coated tablets contain imatinib mesylate equivalent to 100┬ámg or 400 mg of imatinib free base.
GLEEVEC (IMATINIB) is indicated for the following:
Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)
Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase.
Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy
Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.
Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL)
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia.
Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL)
Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)
Adult patients with myelodysplastic/ myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.
Aggressive Systemic Mastocytosis (ASM)
Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown.
Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL)
Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.
Dermatofibrosarcoma Protuberans (DFSP)
Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.
Kit+ Gastrointestinal Stromal Tumors (GIST)
Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors.
Adjuvant Treatment of GIST
Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
Media Articles Related to Gleevec (Imatinib)
Generic Gleevec Will Likely Cut Millions in Health Costs
Source: MedicineNet Leukemia Specialty [2016.03.21]
Title: Generic Gleevec Will Likely Cut Millions in Health Costs
Category: Health News
Created: 3/18/2016 12:00:00 AM
Last Editorial Review: 3/21/2016 12:00:00 AM
New hope for a type 2 diabetes cure
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.03.29]
Leukemia drug holds promise for patients with type 2 diabetes.The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic...
Using generic cancer drug could save many millions of dollars
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.03.16]
New research suggests little risk, huge financial upside of putting patients with chronic myeloid leukemia on generic form of Gleevec.
Study finds new drug is potent treatment for CML
Source: The Doctors Lounge - Hematology
AMN107, is about 20 times more potent than Gleevec and is effective in treating Gleevec-resistant disease.
Published Studies Related to Gleevec (Imatinib)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. [2011.09]
BACKGROUND: Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic phase after a minimum follow-up of 12 months. We present data from the Evaluating Nilotinib Efficacy and Safety in clinical Trials-newly diagnosed patients (ENESTnd) study after a minimum follow-up of 24 months... INTERPRETATION: Nilotinib continues to show better efficacy than imatinib for the treatment of patients with newly diagnosed CML in chronic phase. These results support nilotinib as a first-line treatment option for patients with newly diagnosed disease. FUNDING: Novartis. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. [2011.07]
To assess the hypothesis that the dynamics of plasma angiogenic and inflammatory cytokines after docetaxel chemotherapy with or without the c-kit/abl/platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate for prostate cancer are associated with outcome, the kinetics of 17 plasma cytokines before versus after chemotherapy were assessed and associations with progression-free survival (PFS) examined...
Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. [2011.05.01]
The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment. This review evaluates the clinical efficacy and safety of imatinib for adjuvant treatment of localized KIT (CD117)-positive resected GIST... This study adds to the evidence (based on one RCT and a number of observational studies) that GIST patients treated with adjuvant imatinib therapy show an improvement in recurrence-free survival compared to placebo or no treatment after resection of KIT-positive localized GIST with tolerable toxicity.
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. [2011.04.20]
PURPOSE: Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory. Optimization of treatment is warranted... CONCLUSION: Treatment of early-phase CML with imatinib can be optimized. Early high-dose therapy followed by rapid adaptation to good tolerability increases the rate of MMR at 12 months. Achievement of MMR by month 12 is directly associated with improved survival.
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. [2011.02.15]
BACKGROUND: The role of surgery in the management of patients with advanced gastrointestinal stromal tumors (GIST) in the era of imatinib mesylate (IM) remains debated. We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial... CONCLUSIONS: Following neoadjuvant IM for non metastatic locally advanced GIST 9 of 25 patients (36%) were selected for resection of the primary tumor. OS and PFS figures were close to those of localised intermediate or high risk GIST (70% at 5 years) in the subgroup of operated patients, while the outcome of the non-operated subgroup was similar to that of metastatic GIST.
Clinical Trials Related to Gleevec (Imatinib)
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas [Active, not recruiting]
This is a second Pilot Study to determine the efficacy of Gleevec« in neurofibromatosis
(NF1) patients with plexiform neurofibromas using new response assessment modalities with
the secondary goals of assessing Gleevec toxicity, and characterizing markers of response.
The rationale for this study arises from the response of human and murine NF1 cells to
Gleevec« in vitro, the response of a NF1 patient treated with Gleevec« for airway
compression by a plexiform neurofibroma with a dramatic response not previously seen in NF1
therapy, and the experience in 37 NF1 patients treated with Gleevec┬« in the initial pilot
study. Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients
with a BSA > 1. 8 m2 or 55 mg/m2 twice daily for patients with BSA < 1. 8 m2. For patients
with a BSA > 1. 8 m2 the dose will increase by increments of 100 mg bid every two weeks as
tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1. 8 m2 the dose
will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum
dose of 220 mg/m2 bid. Treatment will continue for 6 months with an option to continue for
24 months if the patient is deriving a clinical benefit.
Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients [Terminated]
The purpose of this study is to determine maximum tolerated dose of Gleevec in combination
with Chlorambucil in previously treated CLL patients.
Therapy of Early Chronic Phase CML With Gleevec [Completed]
The goal of this clinical research study is to see if imatinib mesylate (Gleevec, STI571)
can improve CML in chronic phase.
To increase the proportion of patients achieving a complete cytogenetic response in patients
with Ph-positive early chronic phase CML using initial Gleevec therapy.
To evaluate the duration of cytogenetic response, duration of hematologic response and
Effect of Antacids on Gleevec´┐Ż in Healthy Volunteers [Completed]
This is a research study that will investigate the effects of antacids (often used to treat
stomach upset) on Gleevec« (a drug that is FDA-approved to treat some types of cancer) in
healthy volunteers. Twelve healthy volunteers (six men and six women) will be recruited to
complete the study. This research study will compare Gleevec« in the body when taken with
and without antacids. Each volunteer will receive a 400 mg pill of Gleevec« on two
occasions. One one occasion they will take the dose of Gleevec« alone. On another
occasion, they will take the Gleevec« 15 minutes after taking a 20 mL dose of antacids.
Several blood samples will be drawn to measure the concentrations of Gleevec┬« and its
breakdown products in the blood, with and without the influence of antacids.
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma [Completed]
- To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with
fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary
- To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in
this cohort of patients.
- To determine the efficacy of imatinib mesylate and paclitaxel in patients with stage
IIIC, IV or recurrent uterine papillary serous carcinoma whose tumor expresses either
c-Kit, PDGFR or abl.
Reports of Suspected Gleevec (Imatinib) Side Effects
Neoplasm Malignant (294),
Oedema Peripheral (116),
Pyrexia (108), more >>